Q.01

What is a product monograph in Canada?

In Canada, a product monograph (PM) is Health Canada's term for the approved reference document for a drug. Health Canada's Guidance Document: Product Monograph defines it as "a factual, scientific document on a drug product that describes the properties, claims, indications, and conditions of use for the drug." It does two jobs: it gives the information needed for the safe and effective use of a new drug, and it serves "as a standard against which all promotion and advertising of the drug can be compared." (Guidance Document: Product Monograph, sections 1.1 and the Glossary)

Legal basis. The term "product monograph" does not appear in the Food and Drug Regulations themselves. The guidance says the PM "contains all the representations to be made in respect of the new drug as required by paragraph C.08.002(2)(k) and C.08.003(2)(h)." In the Regulations:

  • C.08.002, New Drug Submission: a new drug submission must include "a statement of all the representations to be made for the promotion of the new drug." These cover the recommended route of administration, the proposed dosage, the claims, and the contra-indications and side effects [1].
  • C.08.003, supplements: a supplement covers the same representations, plus the withdrawal period (relevant for veterinary drugs) [2].

When one is filed. Under section 1.2 of the guidance, a draft PM "should be included" when any of these is filed, for either a prescription or a non-prescription drug:

  • a New Drug Submission (NDS) or a Supplement to one (SNDS);
  • an Abbreviated New Drug Submission (ANDS) or a Supplement to one (SANDS).

Sponsors "should" start revisions by filing an SNDS or SANDS. Safety-related updates, such as new warnings, precautions or adverse reactions, "are required" when new information becomes available (section 1.4).

Structure (section 2.0):

  • Part 1, Healthcare Professional Information: what is needed to prescribe, dispense and administer the drug. It is also the source of any package insert.
  • Part 2, Scientific Information: animal, clinical trial and microbiology data.
  • Patient Medication Information: plain-language content drawn from Parts 1 and 2.

Current version. The current guidance was adopted on 2024/08/30 and took effect on 2024/12/23. Health Canada's PM index page also lists:

  • the PM Master Template (2024-12-23);
  • a PM FAQ (2020-11-01);
  • an XML PM format with validation rules;
  • a June 2025 notice on new filing requirements for second-language PMs and package insert mock-ups [3].

Language versions and timing. Under Health Canada's Plain Language Labelling Q&A:

  • The first-language PM/Prescribing Information is filed with the submission.
  • The second-language version may follow up to 20 days after the submission is accepted into review.
  • The final second-language version is filed no more than 20 days after the NOC or DIN is issued.
  • The package insert content must match the PM.

[4]

Don't confuse the PM with a class monograph, which is a different instrument. C.01A.001 of the Regulations defines that as "a document prepared by the Department of Health" listing the types and strengths of medicinal ingredients allowed in drugs of a specified class [5].

Approach: I searched the consolidated Food and Drug Regulations (C.R.C., c. 870) and Health Canada's drug guidance catalogue, and read the 2024 product monograph guidance on canada.ca. That guidance's text is not in the datasets.

Q.02

How is it different from the drug label?

In Canadian law the product monograph is not separate from the label. It is one of the things the label covers. The Food and Drugs Act defines "label" broadly, and Health Canada reads that definition to include the product monograph as well as the container labels. In practice, though, "the drug label" usually means the inner and outer labels on the container and package. Those differ from the PM in legal source, audience, content and what gets filed.

One definition covers both

  • The Act: under section 2, "label includes any legend, word or mark attached to, included in, belonging to or accompanying any food, drug, cosmetic, device or package" [6].
  • Health Canada's reading: its Guidance document: Labelling of pharmaceutical drugs for human use (section 3) says this definition "is interpreted to include labels affixed to the container or packaging of the drug, any separate package inserts, product monographs, prescribing information, fact sheets, consumer information/patient medication information (i.e., patient leaflets), patient diaries, or other material containing information specific to the drug product" [7].
  • What falls outside: the same guidance says advertising, promotional material and general disease information "are generally not considered to be drug product labelling" [7].

How the PM differs from the container labels

Inner/outer labelsProduct monograph
What it isThe "inner label" is the label on or affixed to the immediate container. The "outer label" is the label on or affixed to the outside of the package (A.01.010) [8]A separate document with the full scientific and prescribing information
Where the content is setDirectly in the Regulations. C.01.004(1) says the labels "shall show" set items [9]Not spelled out in the Regulations. It holds the representations required under C.08.002 and C.08.003, and its format comes from Health Canada's PM guidance (see my previous answer)
ContentOn the principal display panel: proper/common name, and "Pr" for prescription drugs. On any panel: manufacturer's name and address, lot number, adequate directions for use, quantitative list of medicinal ingredients, expiration date. On the outer label: net amount and, for parenterals, preservatives [9]Indications, contraindications, warnings, adverse reactions, dosage, pharmacology, and clinical and non-clinical data
Ingredient tableNon-prescription drugs for human use need a table on the outer label (C.01.004.02). The rule "do[es] not apply to" prescription drugs [10]Not applicable
ReadersEveryone handling the packPart 1 is for healthcare professionals. The Patient Medication Information section is for patients
Filing (prescription drugs)Mock-ups of the inner and outer labels and packagesThe PM/Prescribing Information itself, "not in mockup format", plus a certification that the package insert "matches the corresponding content" of the PM [4]

Where the PM reaches the package

  • Package insert: for prescribed drugs this is usually the prescribing information document, which "is equivalent to Part 1, Healthcare Professional Information" of the PM. A package insert "is not required". If none is included, sponsors "should include" a label statement such as "Product Monograph, package insert or prescribing Information available on request" [7].
  • Patient leaflet: for new drugs in the PM format, the patient medication information section of the PM "should be provided to the consumer/patient at the point of dispensing or sale". The guidance treats it as "the complete and sufficient product information". Third-party material, such as PAAB-reviewed content, "should not be included in, attached to or distributed with" the package [7]. The labelling guidance still calls this section "Part III" and "consumer information"; the 2024 PM guidance names it "Patient Medication Information".
  • Consistency: the Good Label and Package Practices Guide for Prescription Drugs names a mismatch between the labelled strength and the PM's "Dosage and Administration" section as an error risk. It also notes that critical warnings are often boxed in the PM and shown on the principal display panel of the labels [11].
  • Pharmacy labels: labels that pharmacists put on dispensed drugs are generally a provincial and territorial matter. The guidance notes, though, that the Act's definition of "label" still covers them (for example C.01.005(2)) [7].

Approach: I searched the consolidated Food and Drugs Act and Food and Drug Regulations, and Health Canada's drug labelling guidance: the labelling guidance for human-use drugs, the Plain Language Labelling Q&A, and the Good Label and Package Practices Guide.

Q.03

Where do I find the monograph for a specific drug?

Use Health Canada's Drug Product Database (DPD) Online Query at health-products.canada.ca/dpd-bdpp. Health Canada's PM FAQ (Q2.5) says that "Product Monographs authorized by Health Canada may be accessed from Health Canada's Drug Product Database Online Query." Health Canada's list of its drug databases also describes the DPD as the place to "View product monographs for human drugs" and "View labels for animal drugs" [12].

How to find it

  1. Search for the product. You can search by DIN, or by status, company, product name, active ingredient(s), the 10-digit active ingredient group number, class, route of administration, dosage form or schedule. The search is "NOT case sensitive", and you should not use punctuation such as commas, hyphens, brackets or wildcards (DPD Search Tips).
  2. Check the "Product Monograph" column. In the results, this column comes right after "Class". It shows "YES" when a PM document is available and "NO" when none is currently available. Open the product record to get the PM (same page).
  3. Check that you have the right product. PMs are attached to individual DINs, so one brand can have several records. For example, the DPD lists WEGOVY single-dose prefilled pens under three DINs: 02522551, 02522578 and 02522586 [13][14][15].

The DPD "is updated nightly" (DPD: Access the database).

If no PM shows up (PM FAQ):

  • Some drugs have none (Q2.4). "Most prescription drugs and some non-prescription drugs" have a PM. Drugs "with lengthy market histories and an established safety profile will generally not have an associated Product Monograph."
  • Some are not posted online (Q2.10). One example is Prescribing Information for products authorized before January 2004 that have not filed changes since.
  • Only one language may be posted (Q2.9). Sponsors have had to file the PM in both official languages since June 13, 2015 for prescription drugs and June 13, 2017 for non-prescription drugs. If the second-language PM is missing, either the sponsor has not yet filed the final version or the PM has not been updated since those dates.
  • Ask the sponsor. Products without a package insert "should include" a label statement such as "Product Monograph, package insert or prescribing Information available on request" (from the labelling guidance cited in my last answer) [7].

Related Health Canada sources [12]:

  • Drug and Health Product Portal: Consumer Information taken from the PM, plus Summary Basis of Decision documents, Regulatory Decision Summaries and Summary Safety Reviews.
  • Product monograph brand safety updates table: safety labelling changes made to brand-name PMs, including which sections changed. It is meant to help generic sponsors keep their PMs in line with the Canadian Reference Product. The DPD page says generic manufacturers "must update their PM to ensure it aligns with the Canadian Reference Product."
  • Notice of Compliance database: authorization dates going back to 1994.

Approach: I searched Health Canada's Drug Product Database records and its drug guidance catalogue, and read the DPD access page, the DPD search tips and the PM FAQ on canada.ca. The datasets hold DPD product records but not the PM documents themselves. If you tell me the brand name or DIN, I can look up its DPD record.

Q.04